Share This Page
Drugs in ATC Class C10AB
✉ Email this page to a colleague
Drugs in ATC Class: C10AB - Fibrates
| Tradename | Generic Name |
|---|---|
| ATROMID-S | clofibrate |
| CLOFIBRATE | clofibrate |
| GEMFIBROZIL | gemfibrozil |
| LOPID | gemfibrozil |
| FENOFIBRIC ACID | choline fenofibrate |
| TRILIPIX | choline fenofibrate |
| ANTARA (MICRONIZED) | fenofibrate |
| >Tradename | >Generic Name |
ATC Class C10AB (Fibrates) Market Dynamics and Patent Landscape: What Protects Fenofibrate, Gemfibrozil, and Clofibrate?
The C10AB “fibrates” class remains a mature, generic-driven lipid franchise. Patent estates are mostly expired for core actives in many markets, shifting competitive dynamics to (1) formulation and method-of-use patents, (2) line extensions (micronized/modified-release forms, fixed-dose combinations, and specific dose regimens), and (3) enforcement around exclusivity-linked label features and FDA regulatory exclusivity rather than base compound IP. The biggest near-term “IP leverage” typically sits in specific branded formulations and any remaining line-extension patents that are still listed in regulatory dossiers such as the US FDA Orange Book (for small molecules) and in national registries.
Because fibrates are long-established, most remaining “patent landscape value” is tactical: identify which products still have unexpired patents covering specific strengths, dosage forms, or combinations, then map those to generic entry risk under Hatch-Waxman (US) or national Bolar regimes elsewhere.
Which fibrates dominate ATC Class C10AB and how do patents shape pricing power?
Featured answer: The class is anchored by fenofibrate (often positioned for mixed dyslipidemia and hypertriglyceridemia) and gemfibrozil (primarily for triglyceride lowering). Clofibrate is largely historical in many jurisdictions. Patent-driven pricing power is concentrated in remaining branded formulations or combination products, not in the base actives.
Key commercial levers across C10AB
Fibrate market dynamics are governed more by payer practices and guideline positioning than by brand-level differentiation. Where IP can matter, it typically shows up as:
- Dose form differentiation: micronized fenofibrate versus non-micronized variants, and modified-release profiles when applicable.
- Label and regimen specificity: patents tied to specific indications, patient subsets, or dosing instructions.
- Fixed-dose combinations: where a fibrate is co-formulated or combined with another lipid agent, IP can shift from “fibrate” to “combination” and to the specific ratio and release profile.
- Regulatory exclusivity: even when compound patents are gone, certain data exclusivity and use-linked exclusivity can constrain bios? For fibrates (small molecules), the relevant concept is FDA drug exclusivity and 505(b)(2) exclusivity, not biologics exclusivity.
Where patent estates tend to be weakest
- Base compound patents for fenofibrate and gemfibrozil are generally long expired in major markets.
- Global coverage: many jurisdictions allow generic launch quickly after regulatory triggers once any last-listed formulation/method patents expire.
- Litigation is less frequent at the “molecule” level and more common around specific patents that still list for particular brand SKUs.
What patents protect fenofibrate products in the US and how many claims remain enforceable?
Featured answer: In the US, protection for “fibrates” tends to be dominated by formulation and use patents still listed for specific brand SKUs. The practical task is to map Orange Book listings for each branded product (strength, dosage form, and applicant) to the remaining unexpired patents (composition, formulation, method-of-use, and sometimes process).
Fenofibrate: where remaining IP usually sits
For fenofibrate, residual patent leverage typically occurs in categories like:
- Composition/formulation
- particle size (micronization), excipient systems, tablet/capsule architecture
- modified dissolution profile and bioavailability enhancements
- Method-of-use
- specified dosing regimens
- specific therapeutic goals or patient stratifications (less common than formulation in practice)
- Combination and co-administration architectures
- fixed-dose combination products if any remain branded with listed patents
How to interpret Orange Book relevance for fenofibrate
The Orange Book is SKU-specific. A branded label may share the same active ingredient across multiple strengths or dosage forms, but the patent landscape differs because each NDA/BLA application and each listed patent is tied to a particular formulation and claim scope.
For litigation readiness, the relevant questions are:
- which fenofibrate brand SKU is targeted by a generic ANDAs
- which Orange Book patents are listed for that SKU
- whether those patents are composition/formulation or method-of-use (and whether generic “design-around” is realistic)
What patents protect gemfibrozil in the US and what generic entry risks exist?
Featured answer: Gemfibrozil’s base IP is largely expired, and generic competition tends to be constrained by any remaining listed formulation or use patents tied to specific brand SKUs.
Gemfibrozil: typical remaining protection vectors
- Formulation patents tied to specific dosage forms (tablet formulation characteristics, dissolution behavior)
- Method-of-use label-linked patents (when present)
- Process patents (less frequently decisive in generic challenges because generics often do not need to replicate the same manufacturing method unless the patent claims require a specific product-by-process property)
Generic launch risk drivers
- If Orange Book lists no unexpired patents for the targeted SKU at the time of ANDA submission, the entry risk is low from a Hatch-Waxman standpoint.
- If Orange Book lists unexpired patents, Paragraph IV risk depends on whether the generic can credibly certify “not infringement” or “invalidity,” and whether any court injunction is realistically obtainable based on claim strength.
Do fibrates have meaningful formulation patents like micronization, salt forms, or modified release?
Featured answer: Yes, in practice the most enforceable residual patents for fibrates are formulation-linked, especially for fenofibrate variants where particle size and dissolution behavior are central to bioavailability.
Formulation patent clusters seen in fibrates
- Micronized fenofibrate: particle size distribution, processing parameters, and consistency to achieve bioavailability and stability
- Modified-release dissolution profiles: controlled release profiles, tablet coating and dissolution-limiting excipients
- Excipient systems: specific binder/lubricant combinations and manufacturing methods that affect release and stability
Why formulation patents matter for generic design-around
- Generic substitution is tied to bioequivalence and can avoid infringement by changing formulation variables only if those changes still meet pharmacopeial and regulatory requirements.
- If a formulation patent claims a narrow particle size range, a generic may attempt to target a different range while meeting bioequivalence.
- If a patent claims broader structural features or functional outcomes (for example, required dissolution curves), design-around becomes harder.
When does patent exclusivity for fibrates end and how does it differ from data exclusivity?
Featured answer: For C10AB, most “patent exclusivity” for active ingredients ends years ago; the remaining constraints are usually SKU-specific listed patents (formulation/use) and, in rare cases, regulatory exclusivity triggered by specific NDA routes (505(b)(2) or new formulations).
How to distinguish practical “exclusivity clocks”
- Patent expiration: ends enforceable rights for the specific claims and jurisdictions where those patents are granted.
- Regulatory exclusivity (US FDA):
- applies to market protection for reference drug approvals
- constrains approval timing of ANDAs even if generic patents are cleared in a narrower sense, depending on the exclusivity basis
- Orange Book listed patent expiry:
- drives Paragraph IV litigation and generic “carve-out” timelines
Litigation timeline implication
In the US, even when base compound patents expire, the presence of unexpired listed patents can keep generic entry delayed due to litigation risk, 30-month stay dynamics, and potential settlements.
What Paragraph IV challenges target C10AB fibrates and what do settlement patterns look like?
Featured answer: Where Paragraph IV challenges occur in fibrates, they usually target the remaining listed patents for brand SKU formulations. Settlements often convert patent risk into agreed launch dates and sometimes include non-monetary terms (authorized labeling carve-outs).
Typical settlement pattern in “mature active” franchises
- The generic concedes nothing but agrees to a delayed launch date tied to the expiration of the last relevant listed patent.
- Courts rarely issue broad injunctions at the molecule level; instead, disputes often focus on formulation or method-of-use claims.
- Settlement frequency is high where (1) the remaining patent is strong enough to make litigation expensive and (2) the generic’s economic case requires timely entry.
What matters for business planning
- the “last-to-expire” patent for the exact SKU
- whether the settlement includes an agreed dismissal of specific counts
- whether design-around is allowed through alternate strengths or alternate dosage forms
What is the Orange Book status for key fibrate products like fenofibrate and gemfibrozil?
Featured answer: Orange Book status is product-and-SKU-specific. For any brand remaining in the market, Orange Book listings determine whether generic entry is constrained by unexpired listed patents and what certification pathway an ANDA must take.
How to use Orange Book listings operationally
For each brand SKU under C10AB:
- identify the active ingredient and dosage form
- enumerate listed patents by type (drug substance, drug product, method-of-use, and patents marked for “exclusive use”)
- extract:
- expiration dates
- any pediatric exclusivity (if relevant to the listed patent term)
- whether patents are terminally disclaimed
- map to generic ANDA certifications (when publicly available through litigation dockets)
Practical “most important” patent list
Business planning should track:
- “last-to-expire” listed patent(s) for each SKU
- method-of-use patents with strong label linkage
- formulation patents with narrow claim scope (design-around possibility)
How does patent strength for fibrates compare with high-growth lipid therapies like PCSK9 inhibitors?
Featured answer: Patent strength in fibrates is usually weaker today because base compound protection is expired. By contrast, high-cost lipid therapies with biologics or small-molecule novel mechanisms typically have longer, later-stage patent estates with high barriers to generic substitution.
Competitive implication
- Fibrates compete on breadth of generic availability and guideline placement.
- Newer lipid therapies maintain pricing power because their patent estates and regulatory pathways create larger entry barriers.
- For fibrates, any remaining pricing premium is usually tied to:
- brand persistence strategies
- payer contracting behavior
- remaining formulation differentiation and label positioning
Which countries are most exposed to generic entry in fibrates and why?
Featured answer: Generic entry risk is highest where (1) local patent coverage is narrow or less consistently enforced and (2) patent term adjustments and linkage regimes do not extend protections beyond expiry of listed claims. In many mature markets, fenofibrate and gemfibrozil are already widely generic.
Jurisdictional dynamics that influence generic entry
- Patent linkage strength (US is linkage-heavy via Orange Book; other systems vary)
- Enforcement intensity (injunction availability and litigation cost)
- Patent quality (composition/formulation patents sometimes have narrower scope and easier invalidation)
- Bolar and early work exceptions affecting readiness of generics at the time of expiry
How do fibrate formulation patents create IP barriers for contract manufacturers and generic developers?
Featured answer: Formulation-linked patents can impose product-development constraints even when the generic active ingredient is free. Barriers are driven by:
- requirements to meet specific dissolution profiles or particle size distributions
- manufacturing process features that are claim-relevant
- stability and bioavailability constraints that make “close” formulations difficult
Manufacturing and IP intersection points
- Micronization/particle size control: if claim scope includes a specific particle distribution, manufacturing variability becomes an infringement risk vector.
- Coating and excipient sourcing: specific excipient profiles can land in claim scope.
- Process parameters: if patents claim specific process steps that yield a specific product property, “different process, same product property” can still create risk.
What patent estate supports combination therapies that include fibrates?
Featured answer: When a fibrate is part of a combination regimen (fixed-dose or co-pack), the patent estate tends to shift from the fibrate alone to the combination product concept, dosing ratio, and release profile.
Combo-focused patent categories
- composition claims for fixed-dose ratios
- tablet/capsule structure and release characteristics
- method-of-use claims for combination regimens when supported by clinical rationale
Market dynamic
Combination products can hold onto brand value longer if:
- they obtain label positioning that payers accept
- they clear regulatory requirements faster than a free-active monotherapy switch
- they retain unexpired combination-specific patents or regulatory exclusivity
Key Takeaways
- C10AB fibrates are mature, with limited remaining base-compound patent leverage; remaining protection is usually SKU-specific formulation or method-of-use IP.
- The most material decision point for market entry timing is Orange Book “last-to-expire” for the targeted brand strength and dosage form.
- Generic entry risk is driven less by the active ingredient and more by unexpired listed patents tied to micronization, dissolution behavior, or label-linked regimens.
- Patent litigation and settlements in fibrates, where they occur, typically resolve around formulation/use claims, often producing agreed launch dates rather than broad, enduring injunctions.
- Near-term differentiation in C10AB usually comes from payers, contract positioning, and any surviving formulation/combination exclusivity, not from molecule novelty.
FAQs
- Which fibrate dosage forms are most likely to have unexpired formulation patents?
- How do Paragraph IV certifications differ for drug product patents versus method-of-use patents in fibrates?
- What settlement terms most often delay generic fibrate launches, and how are “trigger dates” defined?
- Which jurisdictions provide the strongest patent linkage enforcement for fibrate generics?
- How can a generic team design around a micronized fenofibrate formulation patent while meeting bioequivalence?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Hatch-Waxman Act framework and FDA guidance materials on ANDA Paragraph IV certifications. https://www.fda.gov/
- EPO. European Patent Register and related patent family resources. https://register.epo.org/
More… ↓
